EA201992372A1 - Макроциклическое соединение и его применения - Google Patents

Макроциклическое соединение и его применения

Info

Publication number
EA201992372A1
EA201992372A1 EA201992372A EA201992372A EA201992372A1 EA 201992372 A1 EA201992372 A1 EA 201992372A1 EA 201992372 A EA201992372 A EA 201992372A EA 201992372 A EA201992372 A EA 201992372A EA 201992372 A1 EA201992372 A1 EA 201992372A1
Authority
EA
Eurasian Patent Office
Prior art keywords
applications
macrocyclic compound
pharmaceutically acceptable
optionally
activity against
Prior art date
Application number
EA201992372A
Other languages
English (en)
Inventor
Йошито Киши
Казунобо Кира
Кен ИТО
Original Assignee
Президент Энд Феллоус Оф Харвард Колледж
Эйсиай Р Энд Д Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоус Оф Харвард Колледж, Эйсиай Р Энд Д Менеджмент Ко., Лтд. filed Critical Президент Энд Феллоус Оф Харвард Колледж
Priority claimed from PCT/US2018/025887 external-priority patent/WO2018187331A1/en
Publication of EA201992372A1 publication Critical patent/EA201992372A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к новому соединению (1), характеризующемуся эффектом ремоделирования сосудов опухоли и/или активностью против CAF (ассоциированных с раком фибробластов), или его фармацевтически приемлемой соли, необязательно в фармацевтически приемлемом носителе, и их медицинским применениям.
EA201992372A 2017-11-15 2018-04-03 Макроциклическое соединение и его применения EA201992372A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586416P 2017-11-15 2017-11-15
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof

Publications (1)

Publication Number Publication Date
EA201992372A1 true EA201992372A1 (ru) 2020-02-18

Family

ID=69636671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992372A EA201992372A1 (ru) 2017-11-15 2018-04-03 Макроциклическое соединение и его применения

Country Status (1)

Country Link
EA (1) EA201992372A1 (ru)

Similar Documents

Publication Publication Date Title
CY1123666T1 (el) Φαρμακευτικες ενωσεις
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
SA519410259B1 (ar) مركب كبير الحلقات واستخداماته
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MY198004A (en) Antitumoral compounds
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
EA201792121A1 (ru) Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao)
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
AR099880A1 (es) Derivados de nicotinamida como moduladores de trpa1
EA201992372A1 (ru) Макроциклическое соединение и его применения
EA201990443A1 (ru) Новое применение n,n-бис-2 -меркаптоэтилизофталамида
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака